Margaret M. Faul received her B.Sc. and M.Sc degrees from University College Dublin, Ireland. She then moved to the US where she received her Ph.D. degree in synthetic organic chemistry from Harvard University with Professor David A. Evans. In 1993 Margaret joined the Chemical Process group at Eli Lilly and Company, and in 2003 she moved to Amgen where she is currently the Executive Director in the Process Development organization. At Amgen, Margaret is responsible for the commercial process development and process characterization of all molecules in both the synthetic and biologic Amgen portfolio.